Our siRNA #therapeutic for Autosomal Dominant Osteopetrosis Type 2 (ADO2) has been granted both Rare Pediatric Disease Designation and Orphan Drug Designation by the #FDA, a major milestone to bring this revolutionary treatment to patients:https://t.co/uJbYynEExj
Our batteries are recharged and we're preparing to fly to #SanFrancisco for @jpmorgan's Annual Healthcare Conference #JPM23 9-12 Jan.
Email [email protected] to meet our CEO or CFO to learn more about our safe, stable and efficient Bio-Courier #RNA#drugdelivery platform.
We announced today that we have received emergency use authorization (EUA) from the U.S. FDA for our BA.4/BA.5 Omicron-targeting #bivalent#COVID19 booster #vaccine, mRNA-1273.222, in children 6 months through 5 years of age.
Read more: https://t.co/yGBMzZpcXx
Our CEO Dr Suzanne Saffie-Siebert and CFO Richard Scarrott will be in San Francisco from 9-12 January sharing updates on our development and opportunities to invest in and partner with our Bio-Courier platform of silicon stabilised hybrid lipid nanoparticles (sshLNP) for safe,
It is the most common chronic inflammatory and neurodegenerative disease of the central nervous system in young adults. It affects 100,000 people in the UK, and 2.3 million globally.
#stemcells#transplantation#AHSCT
https://t.co/d4Dp4S0Cya
Experts will test how #AHSCT affects patients with highly ‘active’ MS failing drug treatment, or as a first-line treatment for patients with the ‘aggressive’ MS.
The findings could revolutionise care for thousands of people who have MS.
Therapeutic siRNA: State-of-the-Art and Future Perspectives by Maik Friedrich & Achim Aigner
Gene knockdown via RNA interference can be induced by small interfering RNAs and opens novel avenues towards innovative therapies in many diseases. #openaccess
https://t.co/hreCQCen6T
Early detection of #PancreaticCancer Hirotsu Bio Science developed a new test (N-Nose®) by tweaking the genetic code of the nematodes (C. elegans). Users send a urine sample to a lab. Test in US by 2023. #early-diagnostic testing
https://t.co/YOKiX33Hsu
Researchers have developed a #mRNA lipid nanoparticle vaccine that contains antigens from all 20 known subtypes of influenza A & B viruses—a strategy that may serve as the basis for universal flu vaccines.
📄: https://t.co/7GapDbBfxP
#SciencePerspective: https://t.co/fr5juxizRN
AstraZeneca and Merck executives are now raising concerns about how the IRA will impact cancer drug development moving forward.
https://t.co/CIIAg8TAwm
Researchers have found how a specific protein in #SARSCoV2 damages heart tissue in lab models. The group then used the drug 2-deoxy-D-glucose (2DG) to reverse the protein’s toxic effects on the heart. Read more: https://t.co/fPRiiIh81T
Major Congratulations @ArrowheadPharma $ARWR for hitting a home run on 3 major world-changing #ASCVD targets at #AHA22: Olpasiran - Lp(a), APOC3, and ANGPTL3. #RNAi is now the hottest drug modality in town.
https://t.co/dTSSWuqYgb
A medical breakthrough by scientists @imperialcollege could save thousands of heart patient's lives. they have developed beating heart patches which could restore the muscle strength lost after a heart attack. @TheBHF